Multiple myeloma has seen a deluge of new therapies and combination regimens in recent years aiming to extend progression-free survival and improve overall survival – and the flood is far from over.
Karyopharm Therapeutics Inc.'s selinexor may be the next novel agent to win US FDA approval, if the recent extension...






